

# PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  A61K 47/48, 47/26		A1	(11) International Publication Number: <b>WO 99/48535</b>  (43) International Publication Date: 30 September 1999 (30.09.99)
(21) International Application Number: PCT/US99/04268  (22) International Filing Date: 24 March 1999 (24.03.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 09/048,907 26 March 1998 (26.03.98) US  (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/048,907 (CON) Filed on 26 March 1998 (26.03.98)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).  (72) Inventor; and (75) Inventor/Applicant (for US only): KLINE, Douglas, F. [US/US]; Apartment 32, 240 West 15th Street, New York, NY 10011 (US).  (74) Agents: WYATT, Donald, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			

(54) Title: FORMULATIONS FOR PROTECTION OF PEG-INTERFERON ALPHA CONJUGATES

(57) Abstract

The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect PEG-interferon alpha conjugates from loss and degradation during the lyophilization process, as well as degradation during subsequent storage. The formulations of the present invention are suitable for protection of PEG-interferon alpha conjugates from various types of degradation, including, but not limited to loss of biological activity and changes in the degree and/or nature of conjugation. A preferred PEG-interferon alpha conjugate protectable in the formulations of the present invention is an interferon alpha-2b-polyethylene glycol (12,000) conjugate.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## FORMULATIONS FOR PROTECTION OF PEG-INTERFERON ALPHA CONJUGATES

Throughout this disclosure, various publications, patents and patent applications are referenced. The disclosures of these 5 publications, patents and patent applications are herein incorporated by reference.

### Field of the Invention

The present invention pertains to formulations for the stabilization of PEG-interferon alpha conjugates during and after 10 lyophilization, their production and use.

### Background of the Invention

Various natural and recombinant proteins have pharmaceutical utility. Once they have been purified, separated, and formulated, they can be parenterally administered for various 15 therapeutic indications. However, parenterally administered proteins may be immunogenic, may be relatively water insoluble, and may have a short pharmacological half life. Consequently, it can be difficult to achieve therapeutically useful blood levels of the proteins in patients.

20 These problems can be overcome by conjugating the proteins to polymers, such as polyethylene glycol. Davis *et al.*, U.S. Pat. No.

4,179,337 disclose conjugating polyethylene glycol (PEG) to proteins such as enzymes and insulin to obtain conjugates having less immunogenic effect than the original proteins and yet still retaining a substantial proportion of their physiological activity. Veronese *et al.*, (Applied Biochem. and Biotech, 11:141-152, 1985) disclose activating polyethylene glycols with phenyl chloroformates to modify a ribonuclease and a superoxide dimutase. Katre *et al.* U.S. Pat. Nos. 4,766,106 and 4,917,888 also disclose solubilizing proteins by polymer conjugation. Likewise, PEG and other polymers can be conjugated to recombinant proteins to reduce immunogenicity and increase half-life. See Nitecki, *et al.*, U.S. Pat. No. 4,902,502, Enzon, Inc., International Application No. PCT/US90/02133, Nishimura *et al.*, European Patent Application 154,316 and Tomasi, International Application Number PCT/US85/02572. For example, interferon alpha-2b is known to be effective for treatment of disease states such as renal cell carcinoma, AIDS-related Kaposi's sarcoma, chronic and acute hepatitis B, chronic and acute non-A, non-B/C hepatitis and hepatitis C. Improvement of the pharmacological half-life of interferon alpha-2b would improve treatment of these conditions.

While preparation of protein-polymer conjugates is beneficial, they cannot be used in a practical manner unless they can be stored for an extended period of time during manufacture and distribution to health care providers. Some protein-polymer conjugates, however, rapidly deteriorate, even in frozen solutions.

25 Lyophilization (also known as freeze-drying) is a process that can render a pharmaceutical in a form that can overcome this deficiency.

Lyophilization is a process whereby water is sublimed from a composition after it is frozen. In this process, pharmaceuticals and biologicals that are relatively unstable in an aqueous solution over a period of time can be placed into dosage containers in an easily processed liquid state, dried without the use of damaging heat and stored in a dried state for extended periods.

Due to the low total mass of active substance in each dose, the formulations of most pharmaceuticals and biologicals, including protein-polymer conjugates, require additional ingredients to protect the active ingredient during the lyophilization process. For example, a pharmaceutical filled into a dosage container as a low-concentration aqueous solution can be susceptible to physical loss during the lyophilization vacuum process or adsorption to the container. A lyophilized formulation often contains bulking ingredients that increase the amount of solid material, as well as cryoprotectants, lyoprotectants and other stabilizers to protect the active component from damage. Which particular formulation will protect a given type of pharmaceutical, however, must be determined empirically.

There is a present need for a formulation suitable to protect protein-polymer conjugates, and in particular PEG-interferon alpha conjugates, from damage during lyophilization. Such a formulation should allow PEG-interferon alpha-polymer conjugates to maintain their biological activity, physical stability and chemical stability over extended periods of time.

Summary of the Invention

The present invention provides formulations that permit stabilization of PEG-interferon alpha conjugates during and after lyophilization.

5 In one embodiment, the present invention provides aqueous formulations comprising PEG-interferon conjugates, a buffer, a stabilizer and a cryoprotectant. The present invention also contemplates processes for preparing stable, aqueous formulation solutions comprising admixing an effective amount of PEG-interferon  
10 alpha conjugates with a buffer, a stabilizer, a cryoprotectant and a solvent. In a preferred aspect of the process of the present invention, the formulation is prepared and maintained substantially free of dissolved oxygen and a head space of inert atmosphere above the formulation is maintained at a value of less than about 4%  
15 oxygen by volume.

The present invention is not limited to specific chemicals for the solution components. However, in a preferred embodiment, the buffer is sodium phosphate, the stabilizer is a poly(oxy-1,2-ethanediyl) derivative, the cryoprotectant is sucrose and the solvent  
20 is water. In such an embodiment, the sodium phosphate can comprise sodium phosphate dibasic anhydrous with sodium phosphate monobasic dihydrate.

The present invention is also not limited by the concentrations of the components of the formulations of the present invention. In  
25 one embodiment, the concentration of PEG-interferon alpha conjugates is preferably 0.03 to 2.0 mg interferon alpha per ml,

while the concentration of sodium phosphate is preferably 0.005 to 0.1 molar, the concentration of poly(oxy-1,2-ethanediyl) derivative is preferably 0.01 to 1.0 mg/ml and the concentration of sucrose is preferably 20 to 100 mg/ml. In a particularly preferred embodiment, the mass of PEG-interferon conjugates is 0.1 mg of interferon alpha, the mass of sodium phosphate dibasic is 0.75 mg, the mass of sodium phosphate monobasic dihydrate is 0.75 mg, the mass of sucrose is 40 mg, the mass of poly(oxy-1,2-ethanediyl) derivative is 0.05 mg and the volume of water is 0.5 ml.

5 Alternatively, the ratio of components is 0.08% of said PEG-interferon alpha conjugates as measured by the mass of the interferon alpha, 3.6% of sodium phosphate, 0.12% of poly(oxy-1,2-ethanediyl) derivative and 96.2% of sucrose, by weight

10 While the present invention is not limited to a specific PEG-interferon alpha conjugate, in one embodiment, the PEG-interferon alpha conjugates comprise single PEG molecules conjugated to single interferon molecules. In such an embodiment, the interferon alpha molecules can be selected from the group consisting of interferon alpha-2a, interferon alpha-2b, interferon alpha-2c and consensus interferon. In a preferred embodiment, the interferon molecules are interferon alpha-2b. Likewise, while the present invention is not limited to a specific PEG molecule, in one embodiment, the polyethylene glycol is PEG<sub>12000</sub>. In a particularly preferred embodiment, the interferon alpha-2b molecules are linked to the 15 PEG<sub>12000</sub> molecules with a urethane bond.

20

25

While not limited to a specific characterization, when single interferon alpha molecules are linked to single polymer molecules, the present invention contemplates that the resulting PEG-interferon alpha conjugates can comprise a mixture of positional isomers. In a 5 preferred embodiment, one of the positional isomers is an interferon alpha-2b molecule linked to a PEG<sub>12000</sub> molecule at a histidine residue on the interferon alpha-2b molecule.

The present invention also contemplates a process of lyophilization, comprising lyophilization of the formulations 10 described above to create a lyophilized powder. In a preferred embodiment, the process further comprises reconstitution of the lyophilized powder with water or other aqueous diluents, such as benzyl alcohol-containing bacteriostatic water for injection, to create a reconstituted solution (Bacteriostatic Water for Injection, Abbott 15 Laboratories, Abbott Park, IL).

The present invention also contemplates lyophilized powders produced by lyophilization of the formulations described above. In a preferred embodiment, the lyophilized powder comprises 0.08% of said PEG-interferon alpha conjugates, 3.6% of said sodium phosphate, 20 0.12% of said poly(oxy-1,2-ethanediyl) derivative and 96.2% of said sucrose, by weight.

Likewise, articles of manufacture comprising a syringe or a vial containing an effective amount of such lyophilized powders is contemplated. In a preferred embodiment, the article of 25 manufacture further comprises a volume of water for reconstitution of the powder. In a particularly preferred embodiment, the powder

is reconstituted with bacteriostatic water. In a further preferred embodiment, the lyophilized powder is reconstituted with the same volume of water as was removed from the lyophilization solution during lyophilization.

5 The present invention also contemplates processes for treating diseases in animals. In one embodiment, this process comprises the introduction of the reconstituted solution into an animal having a disease. In one embodiment, the animal is human. In a preferred embodiment, the human is infected with a hepatitis virus, such as 10 hepatitis C virus. In an alternate preferred embodiment, the human has cancer.

#### Detailed Description of the Invention

"PEG-interferon alpha conjugates" are interferon alpha molecules covalently attached to a PEG molecule. In preferred embodiments, the PEG-interferon alpha conjugates of the present invention comprises interferon alpha-2a (Roferon, Hoffman La-Roche, Nutley, NJ), interferon alpha 2b (Intron, Schering-Plough, Madison, NJ), interferon alpha-2c (Berofor Alpha, Boehringer Ingelheim, Ingelheim, Germany) or consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (Infergen, Amgen, Thousand Oaks, CA).

25 Polymers, on the other hand, are molecules having covalently attached repeating chemical units. Often, the approximate molecular weight of the polymer is designated with a number following the name of the repeated chemical unit. For example, "PEG<sub>12000</sub>" or

"polyethylene glycol (12,000)" refers to a polymer of polyethylene glycol having an average molecular weight of approximately 12,000. In a  $\text{PEG}_{12000}$  polymer, the number of repeated polyethylene glycol units in the polymer is approximately 273. It is understood that 5 these designations are approximate as polymers are manufactured in the form of a mixture having a distribution of chain lengths, giving an average molecular weight, and it is often impossible to manufacture a polymer having a precise and uniform molecular weight or number of repeated units. Various other polymers and 10 their methods for production are well known in the art.

Methods for creating protein-polymer conjugates are also known in the art. For example, U.S. Patent 5,691,154 to Callstrom et al, U.S. Patent No. 5,686,071 to Subramanian et al, U.S. Patent No. 5,639,633 to Callstrom et al, U.S. Patent No. 15 5,492,821 to Callstrom et al, U.S. Patent No. 5,447,722 to Lang et al and U.S. Patent No. 5,091,176 to Braatz et al all provide methods for producing protein-polymer conjugates.

Conjugation of polymers to proteins may result in a single polymer molecule conjugated to a protein or multiple 20 such conjugations to a single protein. The degree of conjugation is dependent upon the reaction conditions and desired result. In a preferred embodiment, the PEG-interferon alpha conjugate in the formulations of the present invention comprises a single interferon alpha-2b conjugated 25 to a single  $\text{PEG}_{12000}$ . In a particularly preferred embodiment, the interferon alpha-2b molecule is linked to the  $\text{PEG}_{12000}$ .

molecule with a urethane bond. Reagents and methods for producing this protein-polymer conjugate can be found in U.S. Patent No. 5,612,460 to Zalipsky and U.S. Patent No. 5,711,944 to Gilbert, et al. When such a protein-polymer 5 conjugate is utilized in the formulation solutions of the present invention, the preferred concentration of PEG-interferon alpha conjugate is 0.03 to 2.0 mg interferon alpha per ml.

When a single interferon alpha molecule is linked to a 10 single polymer molecule, the resulting PEG-interferon alpha conjugates may be in the form of a single positional isomer or in a mixture of positional isomers. A "mixture of positional isomers" indicates that the individual PEG-interferon alpha conjugates may be linked at different sites 15 on different interferon alpha molecules. For example, in one embodiment of the present invention, the PEG-interferon alpha mixture contains at least one PEG-interferon alpha conjugate linked at a histidine residue of the interferon alpha molecule, while another PEG-interferon alpha 20 conjugate is linked at another site of the interferon alpha molecule (e.g. the amino terminus).

As described above, preservation of PEG-interferon alpha conjugates can be achieved by lyophilization.

Lyophilization is a process of freeze-drying a composition 25 wherein a frozen aqueous mixture is treated to remove water. Commonly, the process involves the sublimation of

water from the frozen aqueous solutions, usually under reduced pressure conditions. After lyophilization, the PEG-interferon alpha conjugate can be stored for extended periods of time.

5 PEG-interferon alpha conjugates, however, are subject to damage during and after lyophilization. Damage to PEG-interferon alpha conjugates can be characterized by the loss of protein, loss of biological activity or by the change in the degree and/or nature of conjugation of the interferon alpha.

10 For example, a PEG-interferon alpha conjugate may degrade into free PEG and interferon alpha, resulting in a lowering of the degree of conjugation. Likewise, the resulting free PEG may become available to conjugate to another interferon alpha, potentially resulting in the increase of the degree of 15 conjugation in that target molecule. Similarly, a PEG-interferon alpha conjugate may undergo an intramolecular shift of the PEG from one site of conjugation to another within the same molecule, thereby changing the nature of conjugation of the interferon alpha.

20 The present invention protects PEG-interferon alpha conjugates from damage by including them in formulations that prevent damage during and after lyophilization. While the present invention is not limited to a particular formulation, in a preferred embodiment, the method utilizes 25 a buffer, stabilizer, cryoprotectant and solvent, in addition to the PEG-interferon alpha conjugate.

Buffers are suitable for maintaining the pH of the formulation in a range of 4.5 to 7.1, preferably 6.5-7.1 and most preferably 6.8. The use of a buffer system of sodium phosphate dibasic and sodium phosphate monobasic is 5 preferred. When a sodium phosphate dibasic anhydrous/monobasic dihydrate system is utilized, it is preferably in equal mass amounts of dibasic to monobasic at a preferred total concentration of 0.005 to 0.1 molar. Other suitable buffer systems to maintain the desired pH range 10 include sodium citrate/citric acid and sodium acetate/acetic acid.

A stabilizing agent is useful to prevent adsorption of the PEG-interferon alpha conjugate to the stainless steel and glass surfaces of the equipment used to make and store the formulations containing 15 the PEG-interferon alpha conjugate. As one example, poly(oxy-1,2-ethanediyl) derivatives are useful as stabilizing agents. Mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives (Polysorbate 80) is a preferred stabilizing agent. When polysorbate 80 is utilized, the preferred concentration is 0.01 to 1 mg/ml.

20 Cryoprotectants, also known as cryoprotective agents or compounds, are agents that protect chemical compounds, cells, or tissues from the deleterious effects of freezing, such as that usually accompanying lyophilization. In the case of PEG-interferon alpha conjugates, cryoprotectants can protect 25 them from damage, adsorption and loss from vacuum utilized in lyophilization.

While the present invention is not limited to a specific cryoprotectant, examples include, but are not limited to, carbohydrates such as the saccharides, sucrose, sugar alcohols such as mannitol, surface active agents such as the 5 Tweens, as well as glycerol and dimethylsulfoxide. A preferred cryoprotectant is a carbohydrate. A preferred carbohydrate is a saccharide or disaccharide. A preferred disaccharide is sucrose.

Likewise, the present invention is not limited to any 10 particular amount of cryoprotectant used. In one embodiment, cryoprotectants are present in an amount sufficient to allow the PEG-interferon alpha conjugate to be lyophilized. In such an embodiment, cryoprotectants can be present in an amount of 0.05% to 90%, preferably 0.05-50%, 15 and most preferably in an amount of about 0.15% to about 10%, based on the total weight of the PEG-interferon alpha solution. When sucrose is used, the preferred concentration is 20 to 100 mg/ml.

Formulations including an effective amount of biologically 20 active PEG-interferon alpha conjugates are useful in treating disease states, preferably as injectable aqueous solutions. An effective amount means the formulation or powder has an adequate concentration of biologically active component to treat a disease state in an animal. For example, the preferred interferon alpha-2b- 25 PEG<sub>12000</sub> conjugates are suitable for treatment of disease states such as renal cell carcinoma, AIDS-related Kaposi's sarcoma, chronic and

acute hepatitis B, chronic and acute non-A, non-B/C hepatitis and hepatitis C. One solution containing an effective amount of this PEG-interferon alpha conjugate contains 0.03 to 2.0 mg/ml of PEG<sub>12000</sub>-interferon alpha-2b conjugate as measured by protein mass.

5

### Example

10 This example provides a description of a formulation of the present invention and protection of one PEG-interferon alpha conjugate during lyophilization and storage. The PEG-interferon alpha conjugate is introduced in a lyophilization formulation, lyophilized and stored as a dry powder. The components of the formulation are as follows:

15 **Table 1: Formulation for Lyophilization and Storage**

	<u>Component</u>	<u>mg/vial*</u>
	interferon alfa-2b-PEG <sub>12000</sub>	0.1***
	Sodium Phosphate Dibasic Anhydrous	0.75
20	Sodium Phosphate Monobasic Dihydrate	0.75
	Sucrose	4.0
	Polysorbate 80	0.05
	Water for Injection (q.s. ad)	0.5 ml**

\*Amount contained in label volume of 0.5 ml  
25 \*\*Water is sublimed during lyophilization.  
\*\*\*Based on protein mass.

30 After lyophilization, the resulting powder is stored and, over a period of six months, samples are reconstituted with water for analysis. The reconstituted solution is analyzed for protein mass

content, degree of conjugation of the PEG-interferon alpha conjugate, bioactivity and visual clarity. The results are present in Table 2.

Table 2: Stability Data

Stability Data on 100 µg vial

Time months	Temp. °C	Antiviral Assay		Protein Content		Purity of PEG-IFN			Descr.
		× 10 <sup>6</sup> IU/vial*	% LS	µg/vial*	% of Initial	% di-PEG- IFN	% mono PEG-IFN	% IFN	
Initial									
1	5	4.33	76	95.8	95.8	3.90	94.19	1.91	CCS**
	6.60	6.60	115	95.6	95.6	3.70	94.20	2.10	0
	7.50	7.50	131	96.4	96.4	3.84	93.76	2.40	0
	7.30	7.30	128	96.2	96.2	3.52	92.11	4.37	0
3	5	6.60	116	97.1	97.1	3.48	94.27	2.25	0
	6.55	6.55	115	98.0	98.0	3.47	93.82	2.72	0
	6.20	6.20	109	92.6	92.6	3.95	93.60	2.45	0
	6.25	6.25	110	93.3	93.3	3.76	92.96	3.28	0
9	5	6.85	120	94.1	94.1	3.59	94.02	2.39	0
	5.75	5.75	101	96.1	96.1	3.69	92.91	3.40	0
	25								CCS

\* Label fill is 0.5 ml/vial

\*\* CCS: White powder; after reconstitution, a clear, colorless solution, essentially free from visible particles

The results show that the total protein mass content is relatively stable over the nine-month period. Additionally, the change in degree of the monopegylated interferon alfa-2b (*i.e.*, degradation to free interferon and polymer or creation of 5 dipegylated interferon) negligible. The bioactivity as measured by a cell-based antiviral assay remains essentially unchanged. The reconstituted solutions remain clear, colorless and free from visible particles throughout the six-month period. This demonstrates a surprisingly high stability during lyophilization and subsequent 10 storage.

From the above, it is clear that the present invention provides formulations suitable to protect PEG-interferon alpha conjugates 15 from damage during lyophilization and during subsequent storage.

Claims

We claim:

5 1. An aqueous formulation, comprising, PEG-interferon alpha conjugates, a buffer, a stabilizer, a cryoprotectant and a solvent.

2. The formulation of Claim 1, wherein said buffer is sodium phosphate, said stabilizer is a poly(oxy-1,2-ethanediyl) derivative,  
10 said cryoprotectant is sucrose and said solvent is water.

3. The formulation of Claim 2, wherein said sodium phosphate comprises sodium phosphate dibasic anhydrous and sodium phosphate monobasic dihydrate.

15

4. The formulation of Claim 2, wherein the concentration of said PEG-interferon alpha conjugates is 0.03 to 2.0 mg interferon alpha per ml, the concentration of said sodium phosphate is 0.005 to 0.1 molar, the concentration of said poly(oxy-1,2-ethanediyl) derivative is 0.01 to 1.0 mg/ml, and the concentration of said sucrose is 20 to 20 100 mg/ml.

25 5. The formulation of Claim 3, wherein the mass of said PEG-interferon alpha conjugates is 0.1 mg of interferon alpha, the mass of said sodium phosphate dibasic anhydrous is 0.75 mg, the mass of said sodium phosphate monobasic dihydrate is 0.75 mg, the mass of

said sucrose is 40 mg, the mass of said poly(oxy-1,2-ethanediyl) derivative is 0.05 mg and the volume of said water is 0.5 ml.

6. The formulation of Claim 5, wherein said PEG-interferon alpha  
5 conjugates comprise single PEG molecules conjugated to single  
interferon alpha molecules.

7. The formulation of Claim 6, wherein said interferon alpha  
molecules are selected from the group consisting of interferon alpha-  
10 2a, interferon alpha-2b, interferon alpha-2c and consensus  
interferon.

8. The formulation of Claim 7, wherein said polyethylene glycol is  
PEG<sub>12000</sub>.

15

9. The formulation of Claim 8, wherein said interferon alpha  
molecules are interferon alpha-2b.

10. The formulation of Claim 9, wherein said interferon alpha-2b  
20 molecules are linked to said PEG<sub>12000</sub> molecules with a urethane  
bond.

11. The formulation of Claim 10, wherein said PEG-interferon  
alpha conjugates comprise a mixture of positional isomers.

25

12. The formulation of Claim 11, wherein one of said positional isomers comprises said interferon alpha-2b molecule linked to said PEG<sub>12000</sub> molecule at a histidine residue on said interferon alpha-2b molecule.

5

13. A process of lyophilization, comprising lyophilization of the formulation of Claim 12 to create a lyophilized powder.

14. The process of Claim 13, further comprising reconstitution of  
10 the lyophilized powder with water to create a reconstituted solution.

15. The process of Claim 14, wherein said water comprises bacteriostatic water.

15 16. A lyophilized powder, produced by lyophilization of the formulation of Claim 12.

17. The lyophilized powder of Claim 16, wherein said powder comprises 0.08% of said PEG-interferon alpha conjugates as  
20 measured by the mass of the interferon alpha, 3.6% of said sodium phosphate, 0.12% of said poly(oxy-1,2-ethanediyl) derivative and 96.2% of said sucrose, by weight.

18. An article of manufacture, comprising a syringe containing an  
25 effective amount of the powder of Claim 16.

19. The article of manufacture of Claim 18, further comprising a volume of water for reconstitution of said powder.
20. The article of manufacture of Claim 19, wherein said water  
5 comprises bacteriostatic water.
21. An article of manufacture, comprising a vial containing an effective amount of the powder of Claim 16.
- 10 22. The article of manufacture of Claim 21, further comprising a volume of water for reconstitution of said powder.
23. The article of manufacture wherein said water comprises bacteriostatic water.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04268

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K47/48 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 48840 A (SCHERING CORP) 5 November 1998	1
Y	see page 12, line 23 – page 13, line 2; claims 1-9 ---	1-23
Y	WO 96 11018 A (SCHERING CORP ; YUEN PUI HO C (US); KLINE DOUGLAS F (US)) 18 April 1996 see abstract see page 6, line 27-34 see page 7, line 13-31 ---	1-23
Y	WO 96 24369 A (GENETICS INST) 15 August 1996 see claims 1-23 ---	1-23
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

**Actual categories of cited documents :**

- A document defining the general state of the art which is not considered to be of particular relevance
- B earlier document but published on or after the international filing date
- C document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- D document referring to an oral disclosure, use, exhibition or other means
- E document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

1 July 1999

05/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

# INTERNATIONAL SEARCH REPORT

Inte/ onal Application No

PCT/US 99/04268

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 420 049 A (HOFFMANN LA ROCHE) 3 April 1991 see page 2, line 26-32 see page 2, line 43-44 -----	1-23
Y	EP 0 809 996 A (HOFFMANN LA ROCHE) 3 December 1997 see claims 1,12 -----	1-23
Y	WO 95 13090 A (ENZON INC) 18 May 1995 see page 13, line 9-18 -----	1-23
Y	WO 97 18832 A (ENZON INC) 29 May 1997 see page 18, line 15-22 -----	1-23
Y	EP 0 593 868 A (HOFFMANN LA ROCHE) 27 April 1994 see page 10, line 13-18 -----	1-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/US 99/04268

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9848840	A 05-11-1998	US 5908621 A		01-06-1999
		AU 7249098 A		24-11-1998
WO 9611018	A 18-04-1996	US 5766582 A		16-06-1998
		AU 3727995 A		02-05-1996
		BR 9509313 A		27-01-1998
		CA 2201749 A		18-04-1996
		CN 1160355 A		24-09-1997
		CZ 9701104 A		17-09-1997
		EP 0777495 A		11-06-1997
		FI 971486 A		10-04-1997
		HU 77287 A		30-03-1998
		JP 10506912 T		07-07-1998
		NO 971633 A		10-04-1997
		NZ 294464 A		29-03-1999
		PL 319603 A		18-08-1997
		SK 43997 A		08-10-1997
WO 9624369	A 15-08-1996	AU 695129 B		06-08-1998
		AU 4911996 A		27-08-1996
		EP 0820299 A		28-01-1998
		US 5744132 A		28-04-1998
EP 0420049	A 03-04-1991	AT 92334 T		15-08-1993
		AU 636653 B		06-05-1993
		AU 6309890 A		11-04-1991
		CA 2024046 A		29-03-1991
		CN 1050503 A		10-04-1991
		CS 9004328 A		16-12-1992
		DD 298054 A		06-02-1992
		JP 3130232 A		04-06-1991
		MX 22522 A		01-10-1993
		PT 95454 A		22-05-1991
		RU 2008017 C		28-02-1994
EP 0809996	A 03-12-1997	AU 2372397 A		04-12-1997
		BG 101540 A		27-02-1998
		BR 9703421 A		15-09-1998
		CA 2203480 A		30-11-1997
		CN 1167777 A		17-12-1997
		CZ 9701679 A		17-12-1997
		DE 809996 T		09-04-1998
		ES 2110386 T		16-02-1998
		GR 97300063 T		30-01-1998
		HR 970298 A		30-04-1998
		HU 9700959 A		02-03-1998
		JP 10067800 A		10-03-1998
		NO 972480 A		01-12-1997
		NZ 314903 A		28-10-1998
		PL 320251 A		08-12-1997
		SG 55314 A		21-12-1998
		SK 67397 A		10-12-1997
WO 9513090	A 18-05-1995	AU 691225 B		14-05-1998
		AU 1179895 A		29-05-1995
		EP 0730470 A		11-09-1996
		HU 75533 A		28-05-1997
		JP 9506087 T		17-06-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Appl. No.

PCT/US 99/04268

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9513090	A	NZ	276943 A	26-02-1998
		US	5711944 A	27-01-1998
WO 9718832	A	29-05-1997	US 5738846 A	14-04-1998
			AU 7600496 A	11-06-1997
			EP 0862455 A	09-09-1998
EP 0593868	A	27-04-1994	US 5382657 A	17-01-1995
			AT 165102 T	15-05-1998
			AU 668742 B	16-05-1996
			AU 4478093 A	03-03-1994
			BG 98067 A	15-11-1994
			BR 9303469 A	22-03-1994
			CA 2103829 A	27-02-1994
			CN 1088936 A, B	06-07-1994
			CN 1211578 A	24-03-1999
			CN 1173500 A	18-02-1998
			CZ 9301693 A	13-04-1994
			DE 69317979 D	20-05-1998
			DE 69317979 T	20-08-1998
			ES 2116376 T	16-07-1998
			FI 933740 A	27-02-1994
			HR 931094 A	30-06-1997
			HU 67013 A	30-01-1995
			JP 2859105 B	17-02-1999
			JP 6192300 A	12-07-1994
			LT 3174 B	27-02-1995
			LV 10907 A	20-12-1995
			LV 10907 B	20-04-1996
			MW 7693 A	08-06-1994
			MX 9305146 A	31-03-1994
			NZ 248452 A	21-12-1995
			NZ 264872 A	26-01-1996
			OA 9850 A	15-08-1994
			PL 300194 A	05-04-1994
			SI 9300423 A	31-03-1994
			SK 89893 A	06-04-1994
			ZA 9306098 A	01-03-1994
			ZW 11193 A	23-03-1994